Celsentri Dosage/Direction for Use

Testing prior to Initiation of CELSENTRI: Prior to initiation of CELSENTRI, test all patients for CCR5 tropism using a highly sensitive tropism assay. CELSENTRI is recommended for patients with only CCR5-tropic HIV-1 infection. Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on CELSENTRI [see Microbiology and Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Monitor patients for ALT, AST, and bilirubin prior to initiation of CELSENTRI and at other time points during treatment as clinically indicated [see Hepatotoxicity under Precautions].
General Dosing Recommendations: CELSENTRI tablets are taken twice daily by mouth and may be taken with or without food.
CELSENTRI must be given in combination with other antiretroviral medications.
The recommended dosage of CELSENTRI differs based on concomitant medications due to drug interactions.
Recommended Dosage in Adults: Table 10 displays oral dosage of CELSENTRI based on different concomitant medications [see Effect of Concomitant Drugs on the Pharmacokinetics of Maraviroc under Interactions]. (See Table 10.)

Click on icon to see table/diagram/image

Recommended Dosage Recommendations in Patients with Renal Impairment: Table 11 provides dosing recommendations for patients based on renal function and concomitant medications. (See Table 11.)

Click on icon to see table/diagram/image